Analysts Set Liquidia Corporation (NASDAQ:LQDA) Target Price at $43.44

Shares of Liquidia Corporation (NASDAQ:LQDA) have received a consensus recommendation of “Moderate Buy” from the twelve analysts that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $43.4444.

A number of brokerages have recently issued reports on LQDA. Wells Fargo & Company increased their price objective on shares of Liquidia from $44.00 to $51.00 and gave the stock an “overweight” rating in a research note on Monday, March 23rd. Oppenheimer increased their price objective on shares of Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a research note on Thursday, March 12th. BTIG Research boosted their price target on Liquidia from $49.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Needham & Company LLC boosted their price target on Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, March 7th.

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $38.19 on Monday. The firm has a fifty day moving average price of $37.11 and a 200-day moving average price of $32.49. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. The stock has a market cap of $3.36 billion, a PE ratio of -46.01 and a beta of 0.45. Liquidia has a 1 year low of $11.26 and a 1 year high of $46.67.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $92.02 million during the quarter, compared to analysts’ expectations of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. Liquidia’s revenue for the quarter was up 3072.4% on a year-over-year basis. Equities analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Michael Kaseta sold 36,932 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $1,382,364.76. Following the transaction, the chief financial officer directly owned 350,919 shares of the company’s stock, valued at approximately $13,134,898.17. The trade was a 9.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajeev Saggar sold 21,142 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $791,345.06. Following the completion of the transaction, the insider directly owned 176,883 shares in the company, valued at approximately $6,620,730.69. This represents a 10.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 293,398 shares of company stock worth $10,886,538 in the last quarter. 26.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia in the 4th quarter worth approximately $25,000. Covestor Ltd boosted its position in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Liquidia during the 3rd quarter valued at approximately $30,000. FNY Investment Advisers LLC bought a new position in shares of Liquidia during the 3rd quarter valued at approximately $34,000. Finally, NewEdge Advisors LLC bought a new position in shares of Liquidia during the 2nd quarter valued at approximately $25,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).